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The annual meeting of the Society for Industrial Microbiology (SIM) this year was held in Denver,
Colorado, from July 29 to August 2, 2007. Nearly 200 oral and about 120 poster presentations kept
the approximately 600 participants busy for more than 4 days. This report focuses on the 35 talks
dedicated to natural products chemistry, biosynthesis, engineering, drug discovery and develop-
ment, as well as neutraceuticals.Introduction
On Sunday, July 29, the approximately 600 international
participants of the Society for Industrial Microbiology
(SIM) Annual Meeting 2007 came together at the Hyatt
Regency Convention Center in Denver, CO, prepared to
be informed about and to discuss the exciting news and
advances in the sciences and technologies of industrial
microbiology. The following 4 dayswerepackedwith nearly
200 oral and 120 poster presentations covering biocataly-
sis, environmentalmicrobiology, fermentation and cell cul-
ture, industrial eukaryotic microbiology, metabolic engi-
neering, and natural products, yet still left ample time for
the participants to network and discover the local sights
of Denver and its beautiful surroundings. Drs. Kevin Rey-
nolds (Portland State University, Portland, OR) and Ben
Shen (University of Wisconsin, Madison, WI) cochaired
the scientific program on natural products, which featured
6 sessions with 35 oral and approximately 30 poster pre-
sentations. This year’s SIM Annual meeting proved once
again to be the premier venue for natural products chemis-
try, biosynthesis, engineering, drug discovery and devel-
opment, and natural products as neutraceuticals. This re-
view summarizes the highlights from the oral presentations
covering the various aspects of natural products.
Natural Products as Anticancer Agents:
From Discovery to Development
The first session featured six talks illustrating how natural
products were discovered and developed into new anti-
cancer drugs, withDrs.GuyCarter (WyethResearch, Pearl
River, NY) and Ray Lam (Nereus Pharmaceuticals, San
Diego, CA) as cochairs of the session. Dr. Gregory Vite
(Bristol-Myers Squibb Pharmaceutical Research Institute,
Princeton,NJ) started the sessionwith apresentation titled
‘‘Unnatural Selection and the Evolution of Anticancer
Agent Ixabepilone: Optimizing the Fermentation and
Drug-Like Properties of Epothilones’’ that described his
team’s effort to optimize epothilone B production by strain
improvement, followed by a combination of semisyn-
thetic modification and microbial biotransformation of1098 Chemistry & Biology 14, October 2007 ª2007 Elsevier Ltdepothilone B to generate analogs. Evaluation of the resul-
tant analogs for their in vitro activity andmetabolic stability
as well as the in vivo activity in tumor models yielded
ixabepilone (BMS-247550), a novel lactam analog, as a
superior agent for human clinical trials (currently in phase
III). In general, epothilones, first isolated from the myxo-
bacterium Sorangium cellulosum in the mid 1990s, are
very attractive anticancer drug leads, since their mode of
action is identical to that of paclitaxel; epothilones also
have the unique ability to overcome multiple drug resis-
tance and possess other favorable drug-like properties.
However, they are still far from being ideal, and production
of analogs is a viable strategy for obtaining anticancer
compounds with improved properties.
Opening with the statement that 20 marine-derived an-
ticancer agents are currently in various stages of clinical
trials, Dr. William Gerwick (University of California at San
Diego, La Jolla, CA) presented ‘‘Anticancer Drug Discov-
ery from Marine Cyanobacteria: New Molecules Working
by New Mechanisms.’’ Marine cyanobacteria represent
a rich source of novel peptide and peptide-polyketide nat-
ural products (over 800 are known), many of which are
highly cytotoxic to mammalian cells, serving as excellent
anticancer drug leads. The continued effort by theGerwick
lab has resulted in the identification and structure elucida-
tion of numerous marine natural products with new chem-
ical structures and new mechanisms of action. For exam-
ple, coibamide A, produced by a Leptolyngbia species,
features an unprecedented extent of O- and N-methyla-
tion comprising methylated serine, valine, tyrosine, and
threonine residues, is antiproliferative, and apparently
shows a new mechanism of action. Another interesting
example is somocystinamide A, a peptide-polyketide
metabolite isolated from Lyngbya majuscule. A newly de-
veloped screen for caspase 8 activators facilitated the
identification of somocystinamide’s apoptotic activity.
With these and other examples, Dr. Gerwick concluded
that the tide for natural product research is rising and it
is an exciting time for natural product discovery through
the effective combination of chemistry and biology.All rights reserved
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covery and Development of a Novel Proteasome Inhibitor
from a Marine Actinomycete,’’ was given by the session’s
cochair, Dr. Lam. He reported titer improvement, fermen-
tation scale-up, and development of a defined salt fer-
mentation medium for the commercial production of
salinosporamide A at kilogram scale. Salinosporamide A
(NPI-0052), produced by the marine organism Salinispora
tropica, represents a novel inhibitor of the 20S proteasome
and enhances the response to conventional therapy in co-
lon cancer. However, access to a reliable supply of the
compound for further clinical development represented
a great obstacle, since it required the use of saline fermen-
tation. The process of saline fermentation is challenging
due to the commonly used ingredients for marine organ-
isms, such as sea water and animal nutrients, and the
damaging effects of high salt concentrations on the fer-
mentation equipment. The process reported by Dr. Lam
represents the first use of saline fermentation for produc-
tion of salinosporamide A in quantities sufficient for human
clinical application, and the compound has recently en-
tered phase I clinical trials.
‘‘What Do You Do with a Natural Product That Is Too
Toxic’’ was the title Dr. Justin Moran (Wyeth Research,
Pearl River, NY) used to chronicle the discovery and de-
velopment of calicheamicin into a clinical anticancer
drug (Mylotarg). The calicheamicins, discovered in the
mid 1980s from several Micromonospora species, repre-
sent some of the most potent cytotoxic molecules known
to date. A combination of strain improvement, mediumde-
velopment and fermentation optimization resulted in a dra-
matic improvement of calicheamicin titer (by five orders of
magnitude!), but the excitement of this discovery was
dampened by the finding that improved compounds
were too toxic for the safe use in humans. Selective tumor
cell delivery, using monoclonal antibodies, emerged as
a method to overcome the observed extreme toxicity.
First, calicheamicin was attached to a hybrid amide-
hydrazone linker that did not significantly reduce the
potency of the compound and was stable in serum but
hydrolyzed upon internalization where the pH is low. Next,
the anti-CD33 antibody, which targets acute myeloid leu-
kemia cells, was attached to the drug via this hydrazone
linker. After surviving all clinical trials, the resulting com-
plex chemotherapeutic agent was finally commercialized
in 2000 as Mylotarg, representing the first and only FDA
approved antibody-conjugated chemotherapy to date.
Calicheamicin, with several additional targeting opportuni-
ties, is currently undergoing preclinical evaluation.
Dr. Jim McAlpine (Thallion Pharmaceuticals Inc., Saint-
Laurent, QC, Canada) presented a progress report on their
anticancer drug lead titled ‘‘ECO-4601, a Novel Anti-
cancer Pharmacophore, Development through Phase I.’’
ECO-4601 (diazepinomicin), a farnesylated dibenzodiaze-
pinone produced by a Micromonospora strain, was dis-
covered using Thallion’s DECIPHER technology, a geno-
mics based platform for natural product drug discovery,
by predicting the chemical structure of a compound
frommicrobial genome sequences. ECO-4601 representsChemistry & Biologya new pharmacophore with a dual mode of action. It binds
to the peripheral benzodiazepine receptor that plays a role
in apoptosis and also inhibits the Ras signaling pathway.
Production of ECO-4601 has now approached kilogram
scale via strain improvement and fermentation optimiza-
tion, and the recent phase I clinical trials concluded with
a strong safety and tolerability profile without dose limiting
toxicity. ECO-4601 is currently in phase I/II trials and could
be viewed as a validation of the DECIPHER technology for
natural product drug discovery.
Dr. Leonard McDonald (Wyeth Research, Pearl River,
NY) ended the session by reporting Wyeth’s effort on
‘‘Pyranonaphthoquinone Inhibitors of AKT Kinase.’’ AKT,
when activated, promotes cell proliferation and survival.
Specific AKT inhibitors, therefore, could be important can-
cer chemotherapy drug leads. High throughput screening
for AKT inhibition against Wyeth’s synthetic and natural
product libraries resulted in several hits, one of which
was an extract made from a Streptomyces species. The
extract was active for AKT inhibition even after 1000-fold
dilution, and natural product dereplication eventually re-
sulted in the identification of the pyranonaphthoquinones
(e.g., lactoquinomycin) asAKT-specific inhibitors. The pyr-
anonaphthoquinones, which have been reported previ-
ously to be toxic to human tumor cells, and their semisyn-
thetic analogs now serve as excellent small molecule
probes to evaluate AKT biology.
Lipid II-Targeted Antibiotics: Chemistry,
Biosynthesis, and Development
Drs. Stefano Donadio (KtedoGen, Malnate, Italy) and Jon
Thorson (University of Wisconsin, Madison, WI) cochaired
the Monday afternoon session with its six presentations
focusing on lipid II as a common target for antibacterial
agents. Dr. Frank Koehn (Wyeth Research, Pearl River,
NY) started the session with a talk titled ‘‘Mannopeptimy-
cins: Unique Lipid II-Targeted Anti-Infective Agents’’ to
inform the audience about the discovery of the manno-
peptimycins through Wyeth’s look-back program. The
mannopeptimycins, a family of glycopeptides first isolated
from a Streptomyces species in the 1950s, do not block
lipid II synthesis, but rather inhibit the lipid II-dependent
peptidoglycan maturation by binding to lipid II in a way
that is different from other compounds. SAR analysis re-
vealed the need for lipophilic side chains, and a combina-
tion of directed biosynthesis and semisynthetic modifica-
tions was applied to introduce these structural variations.
Finally, an adamantyl substitution on the disaccharide and
a cyclohexyl side chain on the mannopeptimycin core
scaffold resulted in an analog with improved therapeutic
properties. Dr. Koehn concluded that Lipid-II, a well-
known target, still provides novel opportunities, microbial
natural products continue to be a rich source of new drug
leads, and Wyeth continues its natural product program
for anti-infective agents. Through its look-back program,
Wyeth continues to take advantage of its 50+ years of nat-
ural product collections, to incorporate combinatorial bio-
synthesis strategies to further expand natural product
diversity, and to combine the strengths of its synthetic14, October 2007 ª2007 Elsevier Ltd All rights reserved 1099
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ful discovery of novel anti-infective agents.
Next, Dr. James Janc (Theravance, South San Fran-
cisco, CA) presented a talk titled ‘‘Telavancin, a Multifunc-
tional Lipoglycopeptide Antibiotic, Disrupts Both Cell Wall
Biosynthesis and Cell Membrane Integrity,’’ highlighting
their strategy to find novel antibacterial agents based on
the vancomycin scaffold. The novel lipoglycopeptide anti-
biotic telavancin was specifically designed to overcome
the emerging resistancemechanisms against vancomycin
by attaching a lipophilic decylaminoethyl-side chain to the
vancosamine sugar. Due to this structural modification,
telavancin not only inhibits the transpeptidation reaction
in peptidoglycan biosynthesis, as is the case for vancomy-
cin, but it also inhibits the earlier transglycosylation step
by virtue of its affinity for lipid II. As a second mechanism
of action, telavancin disrupts the barrier function of the
bacterial cell membrane. These features ensure that
telavancin retains activity against strains with reduced
susceptibility for vancomycin. Telavancin is currently in
phase III clinical trials.
Dr. Wilfred van der Donk (University of Illinois, Urbana,
IL) presented a progress report on their efforts focusing
on the lantibiotics, titled ‘‘Biosynthesis of the Lantibiotics
Nisin and Haloduracin.’’ Lantibiotics, comprising a class
of more than 60 compounds, are highly potent antibacte-
rial agents. The mode of lantibiotics’ action includes
specific binding to lipid II followed by membrane permea-
bilization. Biosynthesis of class I lantibiotics requires three
enzymes (dehydratase, cyclase, and protease) to gener-
ate the final compound from the peptide precursor. How-
ever, only two genes encoding the modifying enzymes are
found in class II lantibiotic gene clusters. The van der Donk
lab established that, in class II lantibiotic biosynthesis,
both the dehydratase and cyclization activities reside
within one protein, as exemplified by LctM for the lacticins.
These characteristics were exploited to mine microbial
genomes for the discovery of novel lantibiotics, as demon-
strated for the haloduracins from Bacillus halodurans. The
dehydratase domain of LctM was found to have a very
relaxed substrate specificity. Thus, site-directed muta-
genesis of the structural gene, incorporation of nonpro-
teinogenic amino acids by in vitro peptide synthesis, and
even an attachment of a completely different nonlantibi-
otic peptide to the lantibiotic leader peptide all resulted
in dehydration activity, as deduced from the resulting
enzymatic products. With these findings, Dr. van der
Donk ended the talk with a great promise to engineer
novel lantibiotics by manipulating their biosynthetic
machinery.
In the talk titled ‘‘Lipid II Utilizing Enzymes as Antiviru-
lence Targets,’’ Dr. Dewey McCafferty (Duke University,
Durham, NC) reported that the lipid II utilizing enzymes,
sortases, might be good antivirulence targets for treat-
ment of Gram-positive bacterial infections. S. aureus has
two sortase isoforms: sortase A, essential for adhesion
during infection onset, and sortase B, required for heme-
iron acquisition in later stage of infection. The sortase
gene knockouts displayed drastically reduces virulence.1100 Chemistry & Biology 14, October 2007 ª2007 Elsevier LtdScreening and discovery of sortase inhibitors as a novel
strategy for the identification of antibacterial agents were
also discussed.
Dr. Dan Kahne (Harvard University, Cambridge, MA) il-
lustrated how chemical, biochemical, and structural tools
are combined to optimize a lipid II-targeting natural prod-
uct lead in his talk titled ‘‘Dissecting the Structural
Requirements for Moenomycin A Activity Using Semisyn-
thetic Analogs with Modified Phosphoglycerate Lipids.’’
Moenomycin, first discovered in the mid 1960s from
aStreptomyces species, is the only known natural product
that targets the peptidoglycan glycosyltransferase. While
it is several orders of magnitude more potent than vanco-
mycin against many Gram-positive pathogens, its poor
pharmacokinetic properties have so far prevented its clin-
ical application. The Kahne lab developed a modular syn-
thesis that allowed them tomake a variety of moenomycin
analogs with shorter lipid chains and various other modifi-
cations for SAR studies. Analyses of their activity profiles
revealed that the carboxylic acid and phosphate moieties
are very important for enzyme binding, while shorter lipid
chains did not significantly reduce transglycosylase bind-
ing activity. This information should guide production of
analogs with improved biological activity.
Dr. WolfgangWohlleben (University of Tu¨bingen, Tu¨bin-
gen, Germany) concluded the afternoon session by pre-
senting an overview on the biosynthetic pathway of the
glycopeptide antibiotic balhimycin titled ‘‘Glycopeptide
Antibiotics: Biosynthesis, Resistance and Regulation.’’
After a brief review of the balhimycin biosynthetic machin-
ery, various strategies to access balhimycin analogs were
demonstrated. Precursor supply in balhimycin biosynthe-
sis is ensured through one type III polyketide synthase
(PKS) for dihydroxyphenylglycine and through an operon
spanning three genes for b-hydroxytyrosine. The glyco-
peptide backbone is assembled using a nonribosomal
peptide synthetase (NRPS) machinery, and methylation
and glycosylation occur after the release of the peptide
backbone from the NRPS. In contrast, the oxidative cou-
pling reactions as well as the halogenation of b-hydro-
xytyrosine appear to be performed on NRPS-bound inter-
mediates. Given the modular nature of the glycopeptide
biosynthetic machinery, Dr. Wohlleben ended his talk by
posing a question on whether combinatorial biosynthesis
occurs in nature and what the requirements to access
glycopeptide structural diversity by combinatorial biosyn-
thetic methods are.
Discovery and Development of Natural Products:
New Applications and New Targets
The Tuesday morning session, cochaired by Drs. Hiro
Osada (RIKEN, Saitama, Japan) and Kevin Reynolds, con-
sisted of five talks covering several new aspects on natural
product drug discovery. As a starter, Dr. Steve Kendrew
(Biotica, Little Chesterford, UK) reported on ‘‘Biosynthesis
of the Angiogenesis Inhibitor Borrelidin: Precursor-
Directed Biosynthesis of Novel Analogs.’’ Borrelidin, first
discovered in the 1940s from a Streptomyces species, ex-
hibited dual cytotoxicity and anti-angiogenic activity. AfterAll rights reserved
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borrelidin biosynthetic machinery, Dr. Kendrew discussed
various strategies tomodify the borrelidin scaffold with the
goal of separating its anti-angiogenic activity from its cyto-
toxicity. Through directed biosynthesis, a library of borre-
lidin analogs was produced, and one of the analogs,
a C17-cyclobutyl-substituted borrelidin, showed a signifi-
cantly improved profile of angiogenesis inhibition versus
cytotoxicity, demonstrating once again the power of natu-
ral products as drug leads.
Dr. Hiroshi Tomoda (Kitasato University, Tokyo, Japan)
next presented the results on using silkworms to screen
natural products, titled ‘‘Antimicrobial Screen Using Silk-
worms as an In Vivo Infection Model.’’ Like mice, silkworm
larvae have a natural immune system, but they are easier
to handle, available at fairly low cost, and have low space
requirements. Screening more than 5000 culture broths
from actinomycete and fungal strains in silkworm larvae
infected with methicillin-resistant Staphylococcus aureus
(MRSA) or Candida albicans resulted in the discovery of
the nosokomycins, a family of glycopeptides. The nosoko-
mycins are active against MRSA using a mechanism sim-
ilar to that of moenomycin, demonstrating that silkworms
can be used as an effective and selective in vivo infection
model for antimicrobial screening.
With a title of ‘‘Metabolomic and Genomic Analyses of
Streptomyces reveromyceticus, a Producer of an Anti-
Osteoclast Compound,’’ Dr. Hiro Osada’s presentation
summarized his group’s studies of chemistry, biology,
and biosynthesis of the reveromycins. Reveromycin A,
a polyketide with a unique spiroketal moiety first discov-
ered in the early 1990s, induces apoptosis by isoleucyl-
tRNA inhibition specifically in osteoclasts and can there-
fore be a useful compound in treating osteoporosis and
tumor bone metastasis. These new findings initially
prompted the Osada lab to improve reveromycin produc-
tion by strain improvement in order to obtain enough
material for futher biological studies. Next, they cloned
the reveromycin biosynthetic gene cluster, studied its bio-
synthetic machinery, and generated analogs by combina-
torial biosynthetic methods. Reveromycin A was found to
be assembled by a modular PKS with extra domains ac-
counting for the formation of the reveromycin A2 shunt
metabolite. So far no candidate for the formation of the
spiroketal moiety of reveromycin A has been identified.
Finally, the Osada lab sequenced the Streptomyces rever-
omyceticus genome, opening up many additional oppor-
tunities for studying and engineering reveromycin bio-
synthesis.
Dr. Ho Jeong Kwon (Yonsei University, Seoul, South
Korea) illustrated that natural products can not only repre-
sent drug candidates but can also serve as bioprobes/bio-
markers to identify new targets and functions in a talk titled
‘‘Small Natural Molecules Targeting Angiogenesis.’’ Using
the fungal metabolite terpestacin as an example, Dr. Kwon
noted that terpestacin is known to inhibit angiogenesis
in vitro and in vivo, but its mechanism of action remains
poorly understood. The Kwon lab then used a biotinylated
terpestacin for biopanning and thereby identified the gen-Chemistry & Biologeration of reactive oxygen species and the expression of
vascular endothelial growth factor as mechanisms by
which terpestacin exerts its bioactivity.
Dr. Kevin Reynolds presented the last talk for the
morning session titled ‘‘Generation and Analysis Of Novel
Serine/Threonine Protein Phosphatase II Inhibitors.’’ In
general, natural products that act as protein phosphatase
inhibitors are known, and one of them, fostriecin, entered
phase I clinical trials but was withdrawn partly due to drug
stability and purity. Phoslactomycin B, first discovered in
the late 1980s from several Streptomyces species, is an
inhibitor of phosphatase 2A, an enzyme considered to
be a new target for antitumor compounds. The Reynolds
lab has cloned and characterized the phoslactomycin bio-
synthetic pathway and generated a library of phoslacto-
mycin analogs through in vitro enzymatic esterification of
pathway intermediates and in vivo-directed biosynthesis.
Preliminary evaluation of this library showed that some of
the analogs are as potent as the parent natural product.
Phoslactomycin biosynthesis also revealed new insight
into the mechanism of cis-double bond formation in natu-
ral products. Dr. Reynolds concluded that a rich diversity
of new analogs can be generated if all the methods avail-
able (e.g., generating pathway intermediates, in vitro en-
zymaticmodifications, hybrid pathways, and precursor di-
rected biosynthesis) are combined and utilized.
Status and Prospects for Using Natural and
Engineered Compounds as Nutraceuticals
Tuesday afternoon’s session, chaired by Dr. Adam Burja
(Ocean Nutrition Canada, Dartmouth, NS, Canada), was
devoted to nutritionally important natural products and
featured six talks. Dr. Mark Scaife (University of Sheffield,
Sheffield, UK) opened the session with a presentation
titled ‘‘Exploitation of Cyanobacterial Genetics in the De-
velopment of an E. coli-Based Astaxanthin Production
System.’’ The astaxanthins are currently produced by
chemical synthesis, yet the genes encoding astaxanthin
biosynthesis in several cyanobacteria are known. By clon-
ing several beta-carotene ketolase and hydroxylase genes
fromdifferent cyanobacteria species and expressing them
in E. coli, Dr. Scaife showed that beta-carotene can be
efficiently transformed into astaxanthin in the recombinant
E. coli strain in yields up to 4 mg l1 day1, demonstrating
the feasibility of astaxanthin production by fermentation.
Plants are also known to produce astaxanthins, and Dr.
Francis Cunningham (University of Maryland, College
Park, MD) described advances in creating a plant-based
biological production process for astaxanthins. In a talk ti-
tled ‘‘A Study in Scarlet: Using Color Complementation in
E. coli to Unravel the Biochemical Pathway Leading to the
Valuable Red Ketocarotenoid Astaxanthin in the Flowers
of Adonis aestivalis,’’ Dr. Cunningham reported the identi-
fication of two genes from Adonis aestivalis responsible
for conversion of beta-carotene into astaxanthin, setting
the stage to improve astaxanthin production in plants.
Polyunsaturated fatty acids (PUFAs) are another family
of neutraceutically important natural products, and at
least two different pathways for PUFA biosynthesis arey 14, October 2007 ª2007 Elsevier Ltd All rights reserved 1101
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elongation of endogenous fatty acids by elongases and
desaturases. Dr. Helia Radianingtyas (Ocean Nutrition
Canada, Dartmouth, NS, Canada) reported her group’s
findings related to PUFA biosynthesis in a marine fungoid
protist in a talk titled ‘‘Affecting Specific Fatty Acid Pro-
duction within Thraustochytrium sp. ONC-T18.’’ In this mi-
croorganism, PUFAs are made by fatty acid elongation
and desaturation. By adding certain enzyme inhibitors to
the fermentation process, it is possible to direct the forma-
tion of specific PUFAs, thereby allowing better control of
the chain length and chemical properties of the PUFA.
Production of PUFAs in plants was discussed in Dr. Xiao
Qiu’s (University of Saskatchewan, Saskatoon, SK, Can-
ada) presention ‘‘Metabolic Engineering of Microbial Bio-
synthetic Pathways of Very Long Chain Polyunsaturated
Fatty Acids in Plants: Accomplishment and Challenge.’’
By stepwise introduction of increasing numbers of genes
of microbial origin, encoding various steps of PUFA bio-
synthesis, into Brassica juncea, the Qiu lab succeeded
in the production of arachidonic, eicosapentaenoic, and
docosahexaenoic acids in this plant. These findings dem-
onstrated the feasibility of transgenic plants as alternative
sources of PUFAs.
The last group of nutraceutically important natural prod-
ucts discussed were the flavonoids. Isoflavones and their
aglycones are both accumulated and extensively bio-
transformed in soy-based industrial fermentations. In his
talk titled ‘‘Isolation of Isoflavones as Coproducts of the
Erythromycin Fermentation,’’ Dr. Mark Weber (Ferma-
logic, Inc., Chicago, IL) illustrated the development of
a procedure for the recovery of isoflavone aglycones by
acid treatment of the rhamnosylated coproducts, gener-
ated during soy-based fermentations of Saccharopoly-
spora erythraea used for erythromycin production.
Dr. Mark Koffas (The State University of New York at
Buffalo, Buffalo, NY) presented a talk titled ‘‘A Systems
Biology Approach for Plant Secondary Metabolite Optimi-
zation in Microorganisms.’’ Over 500 anthocyanines are
known, and the Koffas lab aims to generate nonnatural an-
thocyanines as food coloring agents and potential drugs
for obesity and diabetes. They first reconstructed the plant
flavonoid pathway in E. coli and Saccharomyces cerevi-
siae by combining enzymes derived from different plant
species. They then optimized the precursor availability
and fermentation conditions. Finally they combined
directed biosynthesis with organic synthesis and demon-
strated a new approach to produce novel flavanones and
dihydroflavonols.
Antibacterial Antibiotics: Discovery, Development
and Resistance
Drs. Ben Shen (author of this report) and Sheo Singh
(Merck Research Laboratories, Rahway, NJ) cochaired
the Wednesday morning session with six presentations
addressing the pressing needs for new antibiotics and
the great challenges of their discovery and development.
Opening the session with a talk titled ‘‘Antibiotic Resis-
tance in Environmental Organisms,’’ Dr. Gerard Wright1102 Chemistry & Biology 14, October 2007 ª2007 Elsevier Ltd(McMaster University, Hamilton, ON, Canada) stressed
the prevalence of antibiotic resistance in environmental
organisms. A survey of the resistance profile of 480 soil-
derived bacterial isolates against 21 commonly used anti-
biotics, both synthetic andnatural-product based, showed
that soil-derived bacteria are resistant to 7.5 antibiotics on
average, with some demonstrating resistance to up to 15
antibiotics! This is a very sobering finding, and multidrug
resistance appears to be the rule rather than the exception
for environmental organisms. Moreover, many resistance
genes isolated from environmental sources were found
to be clustered by their mobilization elements and often
encoded proteins highly similar to their counterparts iso-
lated from clinical samples. Antibiotic resistance is inevita-
ble, and investigation of resistance genes from environ-
mental samples should help predict the potential for
clinical resistance mechanisms.
Dr. David Pompliano (Merck Research Laboratories,
Rahway, NJ) then presented a talk titled ‘‘Antibacterial
Discovery: It’s Not about the Target,’’ summarizing Glaxo-
SmithKline’s sobering experience in a genomics-derived,
target-based approach to screen for new classes of drugs
with novel modes of action. Over a period of 7 years start-
ing in 1995, this approach resulted in the identification of
more than 360 potential targets, 160 validated targets,
and only 26 hit compounds for these targets. Of the 26
hits, only 5 became lead compounds and, eventually,
none were suitable as drug candidates! These frustrating
results prompted them to consider that a good, estab-
lished target is better than a new target. With this new
rationale inmind, they focused onwell-established targets
and increased the molecular diversity of compounds in
their screens. So far, this new strategy has shown prom-
ise, resulting in six drug candidates entering clinical devel-
opment.
With the controversial title ‘‘Natural Product Discovery:
TheWorst of Times and the Best of Times,’’ Dr. Steve Pro-
jan (Wyeth Research, Cambridge, MA) delivered a provoc-
ative analysis of the good, the bad, and the ugly sides of
anti-infective discovery. The challenges the industry is
facing today are not only scientific and financial, but also
social and governmental policy related. Target-based an-
tibacterial discovery has not been successful. While many
pharmaceutical companies have drastically reduced or
even eliminated their effort to develop natural products
as drug candidates, natural products have done well at
Wyeth, and Wyeth remains committed to natural product
drug discovery. Natural products remain an excellent
source for structural diversity that cannot be matched by
any other small molecules. Furthermore, the technology
for natural product discovery and development has im-
proved dramatically in recent times. It is Dr Projan’s belief
that there is no better time to be doing natural product
drug discovery research and that Wyeth is a great place
to do it.
Dr. James Balkovec (Merck Research Laboratories,
Rahway, NJ) talked about the discovery and development
of the first b-1,3-glucan synthesis inhibitor, caspofungin
(Cancidas), with the title ‘‘From Bugs to Drugs: TheAll rights reserved
Chemistry & Biology
Meeting ReviewDiscovery of Caspofungin.’’ The original natural product,
known as pneumocandin, was first discovered in the
mid 1980s and considered to be a good antifungal lead
because of its few off-target activities and new mecha-
nism of action. However, it suffered from a limited spec-
trum, lack of water solubility, and poor oral bioavailability.
Successive strain improvement to increase the titer and
produce the desired analogs, followed by extensive
medicinal chemistry optimization, improved its activity
spectrum, solubility, and pharmacokinetic properties.
Caspofungin acetate (Cancidas) received FDA approval
in 2001 and recently became the number one intravenous
agent for antifungal treatment in the US and Europe. While
the discovery research was completed in 2 years, it took
nearly 10 years of development effort to bring caspofungin
to the market.
Dr. Sheo Singh next presented the recent discovery of
platensimycin and platencin in the talk titled ‘‘Novel Ap-
proaches for Antibiotic Discovery’’ to showcase how inno-
vation in screen design has helped Merck discover novel
antibacterial leads. Platensimycin and platencin, specific
inhibitors of FabF/FabH, two key enzymes in the fatty
acid biosynthetic pathway in bacteria, were discovered
from an innovative natural product screening program us-
ing a novel RNA silencing technology. The expression of
fabF antisense RNA in Staphylococcus aureus leads to
a decrease in FabF levels and, hence, an increase in sen-
sitivity to FabF-inhibiting compounds. This assay was
used to screen 250,000 extracts made from more than
80,000 strains, and the resulting hits were further con-
firmed by cell-free assay against FabF. Among the FabF
inhibitors identified were platensimycin and platencin,
both of which were produced by several isolates of Strep-
tomyces platensis. Platensimycin and platencin feature an
unprecedentedmolecular scaffold. Both were validated to
be potent FabF inhibitors, with platencin also having a po-
tent FabH inhibitory activity. The dual FabF and FabH in-
hibitory property of platencin should be advantageous in
preventing resistance. Although development of these
leads into therapeutic agents still faces many challenges,
including poor pharmacokinetics and the emergence of
resistance, Dr. Singh concluded his presentation on an
optimistic note that more antibiotics with novel structures
and new modes of action can be discovered by applying
this RNA silencing technology.
Dr. Ben Shen ended the session by a progress report on
his group’s effort to clone, characterize, and engineer
platensimycin biosynthesis, titled ‘‘Biosynthesis of Platen-
simycin and Opportunities of Engineering Novel Platensi-
mycin Analogs.’’ The structures of platensimycin and pla-
tencin were reported in May 2006 and 2007, respectively,
and the Shen lab obtained the platensimycin producing
S. platensis in October 2006. The platensimycin biosyn-
thetic gene cluster has now been cloned and character-
ized, unveiling many unusual features including (1) a rare
chemistry for 3-amino-4-hydroxybenzoic acid biosyn-
thesis, (2) a novel pathway for terpenoid biosynthesis in
bacteria, (3) a common biosynthetic machinery shared
by both platensimycin and platencin, the divergence forChemistry & Biologywhich most likely results from an unprecedented diter-
pene synthase, and (4) candidates for possible resistance
mechanisms. These findings now set the stage to engi-
neer the biosynthetic machinery to direct either platensi-
mycin or platencin production or produce novel analogs.
Dr. Shen pointed out how fast a natural product bio-
synthetic gene cluster can be accessed nowadays. Rapid
accessibility of DNA, solid understanding of underlying
biochemistry for many pathways, and availability of mod-
ern biotechnological techniques puts us in an excellant
position to apply combinatorial biosynthetic strategies to
natural product structural diversity and drug discovery.
Fungal Polyketides: Biosynthesis, Pathogenesis,
and Regulation
The last session on Thursday afternoon, cochaired by Drs.
Liangcheng Du (University of Nebraska, Lincoln, NE) and
Isao Fujii (Iwate Medical University, Iwate, Japan), fea-
tured six presentations dedicated to fungal natural prod-
ucts. Dr. Russell Cox (University of Bristol, Bristol, United
Kingdom) started the session with a talk titled ‘‘Investi-
gations of Fungal Pyridine Biosynthesis: A PKS-NRPS
Megasynthetase.’’ Using xenovulene, squalestatin, and
tenellin as three examples, Dr. Cox first gave an overview
on polyketide biosynthesis in fungi, which features a family
of architecturally very similar iterative type I PKSs. He then
explained how these fungal PKSs can generate an amaz-
ing array of structural diversity by repeatedly using their
single PKS module with all or only some of its domains,
depending on the elongation cycle.
Dr. Liangcheng Du then reported his group’s efforts to
dissect fungal PKS mechanisms in a talk titled ‘‘Biosyn-
thesis of Mycotoxin Fumonisins in Corn Pathogen Fusa-
rium verticillioides.’’ Dr. Du noted that the fungal PKSs
for fumonisin (a nonaketide resulting from 8 cycles of
PKS-catalyzed condensation) and T-toxin (a heneicosa-
ketide resulting from 20 cycles of PKS-catalyzed conden-
sation) are highly homologous in spite of the difference in
the number of condensations during their biosynthesis. By
swapping the fumonisin ketosynthase domain with the
T-toxin ketosynthase domain in the fumonisin producer
F. verticilloides, the Du lab showed that the resulting mu-
tant strain still produced fumonisins. This finding suggests
that the ketosynthase domain alone does not control the
polyketide structure of fumonisins. The Du lab also un-
veiled an unprecedented PLP-dependent chain release
mechanism inpolyketidebiosynthesis that involvesanovel
enzyme, Fum8p, and identified candidates thatmayconfer
mycotoxin resistance.
The statins represent one of the most celebrated
classes of natural product drugs, and Dr. John Vederas
(University of Alberta, Edmonton, AB, Canada) provided
an overview of lovastatin biosynthesis titled ‘‘Recent
Advances in Understanding Lovastatin Biosynthesis in
Aspergillus terreus.’’ While the polyketide side chain of
lovastatin is formed by the LovF PKS, the LovB and
LovC PKS complex has to catalyze minimally 35 reactions
in order to biosynthesize the lovastatin precursor dihydro-
monacolin L from short acyl CoA substrates. Dr. Vederas14, October 2007 ª2007 Elsevier Ltd All rights reserved 1103
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colin L biosynthesis, suggesting that the enoylreductase
domain of LovB is not fully functional and there is intimate
protein-protein interaction between the LovB and LovC
subunits. He also revealed the structure of LovC, which
is monomeric and shares the same fold as the medium
chain fatty acid dehydrogenase. LovB has been overpro-
duced and assayed; solving the structure of LovB would
be a tremendous accomplishment. Biotransformation us-
ing LovD has also resulted in the production of a library of
lovastatin analogs, including simvastatin, a very signifi-
cant feat given its current commercial value.
Aflatoxin is biosynthesized by a complex of two fatty
acid synthase subunits (HexA and HexB) and one iterative
type I PKS (PksA). Dr. Craig Townsend (The Johns Hop-
kins University, Baltimore, MD) disclosed the most recent
findings from his group’s efforts on aflatoxin biosynthesis
in a talk titled ‘‘Understanding Programming in Iterative
Type I Polyketide Synthases.’’ Dr. Townsend discussed
the occurrence of a previously unrecognized N-terminal
domain in PksA and provided evidence that its mysterious
function is to transfer a C6 starter unit formed by HexA and
HexB from the HexA to the PksA acyl carrier protein,
ultimately resulting in the production of the aflatoxin pre-
cursor norsolorinic acid. This newly defined domain,
SAT, for starter unit-ACP transacylase, will greatly aid
the understanding of fungal PKSs.
In a presentation titled ‘‘Polyketide Biosynthesis in Phy-
topathogenic Fungus Alternaria solani,’’ Dr. Isao Fujii pre-
sented the identification of seven reduced-type polyketide
gene clusters from A. solani coding for the biosynthesis of
compounds such as solanapyrone and alternaric acid.
While heterologous expression in Aspergillus oryzae of
PksN comprising a methyltransferase domain resulted in
the production of a new octa-methylated decaketide
(alternapyrone), expression of PksF lacking amethyltrans-
ferase domain led to the formation of eleven new com-
pounds, the two main products of which were char-
acterized as aslanipyrone and aslaniol. These findings
underscore once again the flexibility and versatility of fun-
gal PKSs in synthesizing polyketide natural products.1104 Chemistry & Biology 14, October 2007 ª2007 Elsevier LtdTo conclude the session, Dr. Eric Schmidt (University of
Utah, Salt Lake City, UT) presented his group’s efforts on
the equisetin biosynthetic pathway in a talk titled ‘‘Func-
tional Analysis of Equisetin Biosynthetic Proteins.’’ Equi-
setin is a hybrid polyketide-peptide natural product featur-
ing a tetramic acid moiety. The equisetin synthetase
represents a hybrid PKS-NRPS with similarity to the lova-
statin PKS, except that it contains an additional NRPS
module with a terminal reductase domain. The Schmidt
lab expressed the peptide synthetase portion of this
enzyme in E. coli and demonstrated its tetramic acid syn-
thetase activity. Taken together, these findings shed light
into iterative type I PKS-NRPS for hybrid peptide-
polyketide natural product biosynthesis in fungi.
Concluding Remark
SIM 07 has rejuvenated natural product discovery once
again, and the participants left Denver excited, inspired,
and greatly optimistic; thus, it can be concluded that in
‘‘natural product drug discovery: the times have never
been better.’’ Finally, let us conclude with several key
points that emerged during this meeting: (1) natural prod-
ucts continue to provide unmatched structural diversity for
drug discovery. (2) The track record for natural product-
based drugs and drug leads remains excellent, particu-
larly for anticancer and anti-infective agents. (3) Advances
in natural product biosynthesis and engineering have
made it practical to apply the principles of combinatorial
biosynthesis to strain improvement, novel natural product
discovery, and generation of natural product analogs. (4)
Advances in genomics and associated technologies to ac-
cess biodiversity, innovation in assay and screen design,
and improvement to existing and emergence of new
technologies and instrumentations for detection, derepli-
cation, isolation, and structural elucidation promise rapid
access to an ever increasing pool of natural products. (5)
Integration of natural products chemistry with synthetic
chemistry, medicinal chemistry, pharmacology, biology,
and associated disciplines ensures a greater chance to
advance natural product leads into therapeutic drugs.
We look forward to theSIM08 inSanDiego next summer.All rights reserved
